Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative condition, mainly
characterized by progressive weakness and wasting of the limbs, the respiratory and bulbar
muscles. Respiratory insufficiency leads to a fatal outcome after a mean diseases duration of
only three to five years. The disease is characterized by pathological accumulations of a
protein called TDP-43, which can be found large cortical and sub-cortical areas of
post-mortem ALS brains.
No causal treatment for this condition is known to date, and there is a large unmet need to
develop new strategies in order to halt or slow down its progression.
The aim of this study is to test the safety and tolerability of Tideglusib, a treatment that
is already in clinical trials for other neuromuscular conditions, in patients with ALS. It is
assumed that this drug may have a significant therapeutic benefit in this population due to
his mode of action: In the ALS mouse model, Tideglusib decreases significantly the amount of
accumulated TDP-43 proteins within the cells.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Geneva
Collaborators:
Cantonal Hospital of St. Gallen University of Bern University of Lausanne Hospitals University of Zurich